Zama Daniele, Bossù Gianluca, Leardini Davide, Muratore Edoardo, Biagi Elena, Prete Arcangelo, Pession Andrea, Masetti Riccardo
Pediatric Oncology and Hematology Unit 'Lalla Seràgnoli,' Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 11, Bologna, 40137, Italy.
Department of Pediatrics, 'Lalla Seràgnoli,' Hematology-Oncology Unit, University of Bologna, Italy.
Ther Adv Hematol. 2020 Jan 20;11:2040620719896961. doi: 10.1177/2040620719896961. eCollection 2020.
The gut microbiota (GM) is able to modulate the human immune system. The development of novel investigation methods has provided better characterization of the GM, increasing our knowledge of the role of GM in the context of hematopoietic stem-cell transplantation (HSCT). In particular, the GM influences the development of the major complications seen after HSCT, having an impact on overall survival. In fact, this evidence highlights the possible therapeutic implications of modulation of the GM during HSCT. Insights into the complex mechanisms and functions of the GM are essential for the rational design of these therapeutics. To date, preemptive and curative approaches have been tested. The current state of understanding of the impact of the GM on HSCT, and therapies targeting the GM balance is reviewed herein.
肠道微生物群（GM）能够调节人体免疫系统。新型研究方法的发展使人们对GM有了更好的认识，增加了我们对GM在造血干细胞移植（HSCT）背景下作用的了解。特别是，GM会影响HSCT后出现的主要并发症的发生发展，对总体生存率产生影响。事实上，这一证据凸显了在HSCT期间调节GM可能具有的治疗意义。深入了解GM的复杂机制和功能对于合理设计这些治疗方法至关重要。迄今为止，已对预防性和治愈性方法进行了测试。本文综述了目前对GM对HSCT的影响以及针对GM平衡的治疗方法的理解现状。
